Your browser doesn't support javascript.
SARS-CoV-2 IgG seropositivity after the severe Omicron wave of COVID-19 in Hong Kong.
Poon, Rosana Wing-Shan; Chan, Brian Pui-Chun; Chan, Wan-Mui; Fong, Carol Ho-Yan; Zhang, Xiaojuan; Lu, Lu; Chen, Lin-Lei; Lam, Joy-Yan; Cheng, Vincent Chi-Chung; Wong, Samson S Y; Kok, Kin-Hang; Yuen, Kwok-Yung; To, Kelvin Kai-Wang.
  • Poon RW; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Chan BP; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Chan WM; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Fong CH; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Zhang X; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Lu L; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Chen LL; Centre for Virology, Vaccinology and Therapeutics, Hong Kong Science and Technology Park, Pak Shek Kok, Hong Kong Special Administrative Region, People's Republic of China.
  • Lam JY; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Cheng VC; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Wong SSY; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Kok KH; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • Yuen KY; Department of Microbiology, Queen Mary Hospital, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
  • To KK; State Key Laboratory for Emerging Infectious Diseases, Carol Yu Centre for Infection, Department of Microbiology, School of Clinical Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Pokfulam, Hong Kong Special Administrative Region, People's Republic of China.
Emerg Microbes Infect ; 11(1): 2116-2119, 2022 Dec.
Article Dans Anglais | MEDLINE | ID: covidwho-1956544
ABSTRACT
The SARS-CoV-2 Omicron variant has led to a major wave of COVID-19 in Hong Kong between January and May 2022. Here, we used seroprevalence to estimate the combined incidence of vaccination and SARS-CoV-2 infection, including subclinical infection which were not diagnosed at the acute stage. The overall seropositive rate of IgG against receptor binding domain (anti-RBD IgG) increased from 52.2% in December 2021 to 89.3% in May 2022. The level of anti-RBD IgG was lowest in the 0-9 and ≥80 year-old age groups in May 2022. The seropositive rate of antibody against ORF8, which reflects the rate of prior infection, was 23.4% in May 2022. Our data suggest that although most individuals were either vaccinated or infected after the fifth wave, children and older adults remain most vulnerable. Public health measures should target these age groups in order to ameliorate the healthcare consequences of upcoming waves.
Sujets)
Mots clés

Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: COVID-19 Type d'étude: Études expérimentales / Étude observationnelle / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte très âgé / Enfant / Humains Pays comme sujet: Asie langue: Anglais Revue: Emerg Microbes Infect Année: 2022 Type de document: Article

Documents relatifs à ce sujet

MEDLINE

...
LILACS

LIS


Texte intégral: Disponible Collection: Bases de données internationales Base de données: MEDLINE Sujet Principal: COVID-19 Type d'étude: Études expérimentales / Étude observationnelle / Essai contrôlé randomisé Les sujets: Vaccins / Variantes Limites du sujet: Adulte très âgé / Enfant / Humains Pays comme sujet: Asie langue: Anglais Revue: Emerg Microbes Infect Année: 2022 Type de document: Article